Background: Benign pharyngeal ulcers in neonates (Bednar's aphthae) have been reported since 1850. The hypothetical causes include immunological reaction to maternal vaginal flora or formula. As Bednar's aphthae is no longer commonly discussed in the literature, it is underrecognised by perinatal staff, which may lead to unnecessary tests and treatments due to the suspicion of infections including herpes simplex virus. We aimed to evaluate the incidence of Bednar's aphthae.
MATERNAL SILDENAFIL CITRATE IN LABOUR MITIGATES THE INTRAPARTUM DECLINE IN PLACENTAL GROWTH FACTOR LEVELS
Background: Uterine contractions reduce uteroplacental perfusion by up to 60% resulting in placental hypoxia with reperfusion injury and oxidative stress. Placental growth factor (PlGF) levels decline substantially in labour. Sildenafil Citrate (SC), has shown promise for increasing uteroplacental perfusion antenatally. This study aimed to assess the effect of SC administration on PlGF levels in labouring women at term.
Methods: This is subgroup analysis from the RIDSTRESS study (ACTRN12615000319572); a double blind randomised controlled trial assessing the effect of intrapartum SC administration (50mg orally) for the reduction of intrapartum fetal distress. Maternal blood was obtained prior to and 1-4 hours after study medication administration and maternal PlGF levels were quantified.
Results: 33 paired samples of maternal blood were obtained -15 from women receiving SC and 18 from the placebo cohort. There was no significant difference in the demographics of the cohort participants or the interval from treatment to blood sampling (2.5hrs). Pre-treatment PlGF was marginally lower in the placebo cohort [107.4 pg/mL (68.5-182.8) vs 113.2 pg/mL (67.7-171.4) respectively, P = 0.85]. In the placebo group PlGF levels declined [-11 .7 pg/mL (-22.6 --1.0)] whilst in the SC cohort PlGF levels rose [1.2 pg/mL (-29.2-23.4)] post-treatment, with a significant difference seen in the change in levels between the two cohorts [placebo -14.4% (-29.1--1.4) vs SC +3.99% (-18.2-41.4), P < 0.05].
Conclusions: This study provides novel data of the effect of SC on intrapartum maternal PlGF levels, suggesting that SC may mitigate the decline in placental function in labour that arising as a consequence of intermittent hypoxia during contractions. There is limited evidence regarding the pharmacokinetics or the extent of fetal transfer of Sildenafil Citrate (SC) in pregnant women and even less when it is administered during labour. The aim of this study was to assess the concentration of SC and its active metabolite N-desmethyl sildenafil (NDS) in maternal blood and umbilical cord blood from women at term given SC in labour.
PHARMACOKINETICS AND INTRAPARTUM PLACENTAL TRANSFER OF SILDENAFIL CITRATE IN TERM PREGNANCIES
Methods: This is a subgroup analysis from the RIDSTRESS study (ACTRN12615000319572) performed at the Mater Mother's Hospital in Brisbane between 2015-2018. This was a double blind randomised controlled trial assessing the potential of intrapartum oral SC (50mg 8-hourly) compared to placebo for the reduction of intrapartum fetal distress. Maternal blood was obtained 1-4 hours after administration of the first dose of study medication and umbilical cord blood was obtained following delivery. Plasma was separated and stored at -80 C. SC and NDS assays were performed at the Katholieke Universiteit Leuven.
Results: Of the 150 participants administered SC, 33 posttreatment maternal samples and 26 cord blood samples were obtained. There was no significant difference in maternal demographics between the two cohorts. The interval between SC administration and maternal blood sampling was 2.5(1.9-3.2) hours and the interval between last dose of SC and cord blood sampling was 5.6(3.5-6.7)hours. The SC and NDS assays from these samples are currently underway.
Conclusions: This study will provide the first in-vivo evidence of the transfer of SC and its active metabolite NDS to the fetes when administered intrapartum.
